ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

AZD-9291

Osimertinib

HCID 71496458
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
1421373-65-0
標準SMILES
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C
InChIKey
DUYJMQONPNNFPI-UHFFFAOYSA-N
分子式
C28H33N7O2
平均分子量
499.6 g/mol
単同位体質量
499.26957332

概要

Osimertinib is a member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer. It has a role as an antineoplastic agent and an epidermal growth factor receptor antagonist. It is a secondary carboxamide, a member of acrylamides, a member of indoles, a monomethoxybenzene, an aminopyrimidine, a substituted aniline, a secondary amino compound, a tertiary amino compound and a biaryl. It is a conjugate base of an osimertinib(1+).

名称と識別子

優先名称
Osimertinib
IUPAC
N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
現地名
AZD-9291
英語名
AZD-9291
分子式
C28H33N7O2
分子量
499.61

名称と別名

osimertinib1421373-65-0AZD-9291MereletinibAZD9291AZD 9291osimertinibumN-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide3C06JJ0Z2OAZD-9291 FREE BASEN-(2-{[2-(Dimethylamino)ethyl](Methyl)amino}-4-Methoxy-5-{[4-(1-Methyl-1h-Indol-3-Yl)pyrimidin-2-Yl]amino}phenyl)prop-2-EnamideN-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide
名称をさらに表示
N-(2-{[2-(ジメチルアミノ)エチル](メチル)アミノ}-4-メトキシ-5-{[4-(1-メチル-1H-インドール-3-イル)ピリミジン-2-イル]アミノ}フェニル)プロパ-2-エンアミドN-[3-[[4-(1-メチル-1H-インドール-3-イル)ピリミジン-2-イル]アミノ]-4-メトキシ-6-[[2-(ジメチルアミノ)エチル](メチル)アミノ]フェニル]アクリルアミドN-[2-[メチル2-(ジメチルアミノ)エチルアミノ]-4-メトキシ-5-[4-(1-メチル-1H-インドール-3-イル)ピリミジン-2-イルアミノ]フェニル]アクリルアミドN-[2-[メチル[2-(ジメチルアミノ)エチル]アミノ]-4-メトキシ-5-[[4-(1-メチル-1H-インドール-3-イル)-2-ピリミジニル]アミノ]フェニル]アクリルアミドオシメルチニブADZ9291N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide

物性

構造計算による物性

XLogP
3.7
極性表面積
87.6 Ų
水素結合供与体数
2
水素結合受容体数
7
回転可能結合数
10
重原子数
37
形式電荷
0
複雑度
752

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 2 件

Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors

EMA approved medicines: Human medicine

物理化学的性質

融点
188 oC · >188oC (dec.)
比重(密度)
1.19 · 1.19±0.1 g/cm3(Predicted)
貯蔵温度
-20 °C · Hygroscopic, -20°C Freezer, Under inert atmosphere
溶解性
DMSO(微加熱)、メタノール(微加熱)
酸解離定数(Pka)
12.68 · 12.68±0.70(Predicted)
外見
個体
色
淡い黄色からベージュ
InChIKey
DUYJMQONPNNFPI-UHFFFAOYSA-N
SMILES
CN1C2=CC=CC=C2C(C2C=CN=C(NC3C=C(NC(=O)C=C)C(N(C)CCN(C)C)=CC=3OC)N=2)=C1
CAS データベース
1421373 · 1421373-65-0

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P264, P270, P272, P273, P280, P301+P317, P302+P352, P318, P319, P321, P330, P333+P317, P362+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (50%)

毒性情報

Hepatotoxicity · 1 件

Elevations in serum aminotransferase levels are uncommon during osimertinib therapy occurring in 4% to 5% of patients and rising above 5 times the upper limit of the normal range in only 1% or less. In preregistration trials, there was a single incidence of clinically apparent liver injury attributed to osimertinib therapy, but the clinical features and relatedness to therapy were not defined. Since its approval and more widespread use, there have been no published cases of liver injury due to osimertinib.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

hs_code
2933990099

化学と産業

薬理情報

ATC Code · 2 件

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingPlasma protein binding of osimertinib is 95%.
PharmacodynamicsA pharmacokinetic/pharmacodynamic analysis suggested a concentration-dependent QTc interval prolongation of 14 msec (upper bound of two-sided 90% CI: 16 msec) at a dose of osimertinib 80 mg.
Mechanism of Action · 1 件

Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) that predominate in non-small cell lung cancer (NSCLC) tumours following treatment with first-line EGFR-TKIs. As a third-generation tyrosine kinase inhibitor, osimertinib is specific for the gate-keeper T790M mutation which increases ATP binding activity to EGFR and results in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity. Compared to wild-type EGFR, osimertinib has 200 times higher affinity for EGFR molecules with the L858R/T790M mutation _in vitro_.

Biological Half-LifeThe population estimated mean half-life is 48 hours.
Metabolism/Metabolites · 1 件

Osimertinib is metabolized to at least two pharmacologically active metabolites, AZ7550 and AZ5104, that circulate at approximately 10% of the concentration of the parent compound. Biochemical assays have shown that AZ7550 has similar potency and efficacy to osimertinib, while AZ5104 is more potent against mutant and wild-type EGFR. The main metabolic pathways are oxidation (predominantly by CYP3A) and dealkylation.

FDA Pharmacological Classification · 6 件

3C06JJ0Z2O

OSIMERTINIB

Established Pharmacologic Class [EPC] - Kinase Inhibitor

Mechanisms of Action [MoA] - Kinase Inhibitors

関連反応

3 件
反応記録を作成
HRID 1842637 の反応式
HRID 1842637生成物として
HRID 1842638 の反応式
HRID 1842638生成物として
HRID 1842639 の反応式
HRID 1842639生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
ZAD9291
AZD929/Osimertinib
Osimertinib Intermediate 4
N-(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin
osim
CS-943
Ochinib
CHEBI:90943DTXSID5010259612-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)prop-2-enamideN-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamideN-(2-(2-(dimethylamino)ethyl-methylamino)-4-methoxy-5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)phenyl)prop-2-enamideRefChem:58257

データベース識別子

CAS
1421373-65-0
PubChem CID
71496458
DTXSID
DTXSID501025961
ChEMBL
CHEMBL3353410
ChEBI
CHEBI:90943
UNII
3C06JJ0Z2O
EC Number
108-168-8
Nikkaji
J3.291.102A

Mechanisms of Action [MoA] - Cytochrome P450 3A Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 3A4 Inducers

MeSH Pharmacological Classification · 2 件

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Protein kinase inhibitors that inhibit TYROSINE PROTEIN KINASES.

Absorption, Distribution and Excretion · 4 件

The median time to Cmax was found to be 6 hours.

Osimertinib is primarily eliminated through excretion in the feces (68%), to a lesser extent through urine (14%), while only 2% is excreted unchanged.

The mean volume of distribution at steady state is 918 L.

Oral clearance is 14.3 L/hr.

応用分野 · 2 件

説明AZD-9291 (Mesylate), also known as Osimertinib, belongs to a third-generation EGFR (epidermal growth factor receptor) inhibitor. It can be used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in case when the cancer cells carry specific mutations (such as T790M) in the epidermal growth factor receptor. It takes effect through directly binding to the certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) that are frequently found in NSCLC, further causing poor prognosis for late-stage disease. Since it spares wild type EGFR during therapy, it has only limited toxicity.

使用AZD 9291 is an irreversible inhibitor of epidermal growth factor receptor (EGFR) sensitizing and T790M resistance mutations (IC50s = 15-17 nM) while sparing the wild-type form of the receptor (IC50 = 480 nM). It binds the related IGF1R and hERG receptors with significantly reduced potency (IC50s = 2.9 and 16.2 μM, respectively). AZD 9291 has been shown to inhibit tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg and has been tested clinically in patients with advanced EGFR mutant non-small-cell lung cancer.[Cayman Chemical]

上流・下流製品情報

上流原料

Mutated EGFR-IN-13-chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)propanamidアクリロイルクロリドアクリル酸

下流製品

オシメルチニブメシル酸塩
補足説明 · 1 件

定義ChEBI: A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treat ent of EGFR T790M mutation positive non-small cell lung cancer.